Cytoplasmic Expression of G Protein-coupled Estrogen Receptor 1 Correlates with Poor Postoperative Prognosis in Non-small Cell Lung Cancer

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2022 Jun 13

PMID 35693608

Authors

Zhen-Hua Li

Chang Liu

Qing-Hua Liu

Jian Wang

Ying Wang

Yan-Fei Wang

Shou-Jun Deng

Ding-Biao Li

Affiliations

Soon will be listed here.

Abstract

Background: A hormonal role in the development of non-small cell lung cancer (NSCLC) has been well documented, and the classic estrogen receptors (ERs)-ERα and ERβ have been extensively investigated over the past decade. The expression of ERβ was found to be high and display biological activity in NSCLC, but anti-estrogen therapy targeting this receptor has shown limited efficacy for the disease. The third estrogen receptor, G protein-coupled estrogen receptor 1 (GPER1/GPR30), was recently found to be highly expressed in NSCLC. Herein, we aimed to investigate the expression profile of GPER1 and correlate it with clinicopathological factors as well as postoperative prognosis in NSCLC.

Methods: We examined GPER1 and ERβ expression using immunohistochemistry among 183 NSCLC cases, including 132 lung adenocarcinoma (LUAD) with identified epidermal growth factor receptor (EGFR) mutation status and 51 squamous cell carcinoma (SCC) patients. We then conducted correlation analysis between the expression of GPER1 and clinicopathological factors and patients' postoperative prognosis.

Results: Positive expression of GPER1 was categorized into 2 main classes: nuclei-GPER1 (nGPER1) and concurrent nuclei-and cytoplasm-GPER1 (n/cGPER1), according to its subcellular localization. The LUAD with wild-type EGFR (wt-EGFR) had a higher frequency of n/cGPER1 (50%) but a lower frequency of nGPER1 (31%) when compared with those with mutated EGFR (n/cGPER1: 31%, nGPER1: 41%, respectively). The expression of GPER1, regardless of subcellular localization, was positively correlated with tumor stage and lymph node metastasis. The median recurrence-free survival (mRFS) and overall survival (OS) were significantly worse in participants with n/cGPER1 expression than in those with nGPER1 or without GPER1 expression.

Conclusions: This study revealed that GPER1 is aberrantly highly expressed and presents a unique GPER1 expression profile in NSCLC. The n/cGPER1 expression was significantly associated with EGFR mutation status, tumor stage, lymph node metastasis, and poor postoperative prognosis in NSCLC.

Citing Articles

Missense mutations of GPER1 in breast invasive carcinoma: Exploring gene expression, signal transduction and immune cell infiltration with insights from cellular pharmacology.

Zhang Y, Du C, Zhang S, Yu H, Mo H, Yang Q Biomed Rep. 2024; 22(2):22.

PMID: 39720300 PMC: 11668130. DOI: 10.3892/br.2024.1900.

G protein-coupled estrogen receptor activates PI3K/AKT/mTOR signaling to suppress ferroptosis via SREBP1/SCD1-mediated lipogenesis.

Chen J, Zhao R, Wang Y, Xiao H, Lin W, Diao M Mol Med. 2024; 30(1):28.

PMID: 38383297 PMC: 10880371. DOI: 10.1186/s10020-023-00763-x.

Multi-omics identification of GPCR gene features in lung adenocarcinoma based on multiple machine learning combinations.

Xie Y, Pan X, Wang Z, Ma H, Xu W, Huang H J Cancer. 2024; 15(3):776-795.

PMID: 38213730 PMC: 10777041. DOI: 10.7150/jca.90990.

Oestrogen receptor-independent actions of oestrogen in cancer.

Gopinath P, Oviya R, Gopisetty G Mol Biol Rep. 2023; 50(11):9497-9509.

PMID: 37731028 DOI: 10.1007/s11033-023-08793-8.

References

Baik C, Eaton K . Estrogen signaling in lung cancer: an opportunity for novel therapy. Cancers (Basel). 2013; 4(4):969-88. PMC: 3712734. DOI: 10.3390/cancers4040969. View

Ganti A, Sahmoun A, Panwalkar A, Tendulkar K, Potti A . Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol. 2005; 24(1):59-63. DOI: 10.1200/JCO.2005.02.9827. View

Hsu L, Chu N, Lin Y, Kao S . G-Protein Coupled Estrogen Receptor in Breast Cancer. Int J Mol Sci. 2019; 20(2). PMC: 6359026. DOI: 10.3390/ijms20020306. View

Liu C, Liao Y, Fan S, Fu X, Xiong J, Zhou S . G-Protein-Coupled Estrogen Receptor Antagonist G15 Decreases Estrogen-Induced Development of Non-Small Cell Lung Cancer. Oncol Res. 2017; 27(3):283-292. PMC: 7848463. DOI: 10.3727/096504017X15035795904677. View

Barton M, Filardo E, Lolait S, Thomas P, Maggiolini M, Prossnitz E . Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. J Steroid Biochem Mol Biol. 2017; 176:4-15. PMC: 5716468. DOI: 10.1016/j.jsbmb.2017.03.021. View

Marquez-Garban D, Chen H, Fishbein M, Goodglick L, Pietras R . Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids. 2007; 72(2):135-43. PMC: 6662925. DOI: 10.1016/j.steroids.2006.11.019. View

Raso M, Behrens C, Herynk M, Liu S, Prudkin L, Ozburn N . Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 2009; 15(17):5359-68. PMC: 2893045. DOI: 10.1158/1078-0432.CCR-09-0033. View

Haupt S, Caramia F, Klein S, Rubin J, Haupt Y . Sex disparities matter in cancer development and therapy. Nat Rev Cancer. 2021; 21(6):393-407. PMC: 8284191. DOI: 10.1038/s41568-021-00348-y. View

He Y, Du G, Cai B, Yan Q, Zhou L, Chen X . Estrogenic transmembrane receptor of GPR30 mediates invasion and carcinogenesis by endometrial cancer cell line RL95-2. J Cancer Res Clin Oncol. 2012; 138(5):775-83. DOI: 10.1007/s00432-011-1133-7. View

10.

Gonzalez de Valdivia E, Sanden C, Kahn R, Olde B, Leeb-Lundberg L . Human G protein-coupled receptor 30 is -glycosylated and N-terminal domain asparagine 44 is required for receptor structure and activity. Biosci Rep. 2019; 39(2). PMC: 6390128. DOI: 10.1042/BSR20182436. View

11.

Garon E, Siegfried J, Stabile L, Young P, Marquez-Garban D, Park D . Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer. 2018; 123:91-98. PMC: 6118115. DOI: 10.1016/j.lungcan.2018.06.013. View

12.

Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T . Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol. 2008; 27(3):411-7. DOI: 10.1200/JCO.2008.18.3251. View

13.

Lee S, Kim Y, Sung M, Lee M, Han J, Kim H . Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation. Int J Mol Sci. 2019; 20(19). PMC: 6801455. DOI: 10.3390/ijms20194794. View

14.

Ignatov A, Ignatov T, Roessner A, Costa S, Kalinski T . Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat. 2009; 123(1):87-96. DOI: 10.1007/s10549-009-0624-6. View

15.

Wen Y, Chen Y, Duan X, Zhu W, Cai C, Deng T . The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. Clin Exp Med. 2019; 19(4):407-416. DOI: 10.1007/s10238-019-00572-9. View

16.

Samartzis N, Samartzis E, Noske A, Fedier A, Dedes K, Caduff R . Expression of the G protein-coupled estrogen receptor (GPER) in endometriosis: a tissue microarray study. Reprod Biol Endocrinol. 2012; 10:30. PMC: 3443027. DOI: 10.1186/1477-7827-10-30. View

17.

Smida T, Bruno T, Stabile L . Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications. Front Oncol. 2020; 10:137. PMC: 7039860. DOI: 10.3389/fonc.2020.00137. View

18.

Liu C, Liao Y, Fan S, Tang H, Jiang Z, Zhou B . G protein-coupled estrogen receptor (GPER) mediates NSCLC progression induced by 17β-estradiol (E2) and selective agonist G1. Med Oncol. 2015; 32(4):104. DOI: 10.1007/s12032-015-0558-2. View

19.

Pupo M, Bodmer A, Berto M, Maggiolini M, Dietrich P, Picard D . A genetic polymorphism repurposes the G-protein coupled and membrane-associated estrogen receptor GPER to a transcription factor-like molecule promoting paracrine signaling between stroma and breast carcinoma cells. Oncotarget. 2017; 8(29):46728-46744. PMC: 5564519. DOI: 10.18632/oncotarget.18156. View

20.

Fu S, Liu C, Huang Q, Fan S, Tang H, Fu X . Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer. Oncol Rep. 2018; 39(3):1313-1321. DOI: 10.3892/or.2018.6186. View